RCS - Agronomics Limited - Liberation Labs Announce Manufacturing Partnership

AgronomicsAnnouncement

Today 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH7541Ha&default-theme=true

RNS Number : 7541H  Agronomics Limited  08 May 2025

 

  (https://agronomics.im/) Agronomics (https://agronomics.im/) Limited

("Agronomics" or the "Company")

Liberation Labs Announces Manufacturing Partnership with Vivici

Agronomics (LSE: ANIC), a leading listed company in the field of clean food,
is delighted to announce that its portfolio company, Liberation Labs Holdings
Inc. ("Liberation Labs") has announced a manufacturing partnership with Dutch
ingredients startup Vivici (http://www.vivici.com/) B.V. ("Vivici").

Jim Mellon, Executive Chair of Agronomics, said: "Global protein demand is
outstripping supply, and there is a growing need from food companies to invest
in alternatives which are scalable and sustainable. Companies like Vivici,
which have received full FDA approval in the US and have strong financial
backing, are ideal partners. Liberation Labs has made tremendous commercial
strides in 2025, as it establishes itself as the global partner in
commercialising bioproducts, from foods to materials and more. On the back of
the fundraise announced at the start of the year, the signing of the first
commercial contract is a significant step from Mark and the team in the
successful execution of the company's commercial strategy."

To date, Agronomics has invested a total of US$ 27 million (c.£21.9 million)
in Liberation Labs which, subject to audit, is currently carried at £34.1
million. This position represents c.23% of Agronomics' last stated Net Asset
Value as at 31 December 2024.

The full announcement is set out below without any material changes

RICHMOND, Ind. (May 7, 2025) (http://www.liberationlabs.com/) Liberation Labs
(http://www.liberationlabs.com/) today announced a manufacturing partnership
with Dutch ingredients startup (http://www.vivici.com/) Vivici
(http://www.vivici.com/) . Liberation Labs will produce Vivici's flagship
ingredient, Vivitein(TM) BLG, at its Richmond, Indiana facility when
commercial production begins in 2026.

The New Standard of Protein, (https://www.vivici.com/ingredients) Vivitein™
BLG (https://www.vivici.com/ingredients) is a dairy protein
(beta-lactoglobulin) produced through precision fermentation enabling B2B
customers to launch disruptive, differentiated and better overall products to
consumers in the US market. These include clear water-based protein drinks
with innovative flavors, clean protein powders with superior muscle-building
performance and rapid absorption and vegan-friendly protein bars with luscious
chewy textures.

"Vivici is a perfect reference case for our facility - a company seeking
cost-effective and sustainable manufacturing of a novel protein ingredient
that unlocks a range of other healthy and innovative products," said Mark
Warner, founder and CEO of Liberation Labs. "We love what Vivici is doing and
will be proud to play a role in their success."

Liberation Labs is in the late stages of constructing its first
commercial-scale, purpose-built, precision fermentation biomanufacturing
facility with a capacity of 600,000 liters and a fully dedicated downstream
process. The plant will produce a range of bio-based materials, including
building block ingredients for food, chemicals and other industrial products
at a scale and cost that will fill a pressing need among both new and
established consumer packaged goods companies and other industrial
manufacturers.

 "As awareness of the important role protein plays in supporting active
lifestyles continues to grow, American consumers are demanding higher quality
and greater quantities of protein in their diets." said Stephan van Sint Fiet,
CEO of Vivici. "Our partnership with Liberation Labs expands our European
manufacturing capabilities, providing US customers with increased supply
security for Vivitein™ BLG."

About Liberation Labs

Liberation Labs is commercializing precision fermentation with a global
network of purpose-built manufacturing facilities that enable the next wave of
biotechnology advancements to produce bio-based consumer products at scale. We
combine modern technology with fit-for-purpose design to bring reliable and
cost-effective solutions that meet customer demand across the world. Our
flagship facility in Richmond, Indiana is expected to begin production in 2026
and we have begun a feasibility study for a second plant in Saudi Arabia. More
information is available at (http://www.liberationlabs.com/)
www.liberationlabs.com (http://www.liberationlabs.com/) .

 

 Agronomics Limited   Beaumont Cornish Limited  Canaccord Genuity Limited  Cavendish Capital Markets Limited  Peterhouse Capital Limited  33Seconds Limited
 The Company          Nomad                     Joint Broker               Joint Broker                       Joint Broker                Public Relations
 Jim Mellon           Roland Cornish            Andrew Potts               Giles Balleny                      Lucy Williams               Jack Ferris

 Denham Eke           James Biddle              Harry Pardoe               Michael Johnson                    Charles Goodfellow          Calum Warren-Piper

 +44 (0) 1624 639396  +44 (0) 207 628 3396      +44 (0) 207 523 8000       +44 (0) 207 397 8900               +44 (0) 207 469 0936        agronomics@33seconds.co

 info@agronomics.im

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPURPAUPAGAM